Biofrontera AG
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carci… Read more
Biofrontera AG (B8FK) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: 0.022x
Based on the latest financial reports, Biofrontera AG (B8FK) has a cash flow conversion efficiency ratio of 0.022x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€372.00K) by net assets (€17.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biofrontera AG - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Biofrontera AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Biofrontera AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biofrontera AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Baselode Energy Corp
OTCQB:BSENF
|
-0.665x |
|
R. S. Software (India) Limited
NSE:RSSOFTWARE
|
0.244x |
|
Indian Card Clothing Company Limited
NSE:INDIANCARD
|
-0.023x |
|
Friday's Dog Holdings Inc.
PINK:FDOGF
|
-0.025x |
|
Lionheart Holdings Warrant
NASDAQ:CUBWW
|
N/A |
|
Alumexx N.V.
AS:ALX
|
0.571x |
|
Resources & Energy Group Ltd
AU:REZ
|
-0.019x |
|
mVISE AG
XETRA:C1V
|
0.092x |
Annual Cash Flow Conversion Efficiency for Biofrontera AG (2009–2024)
The table below shows the annual cash flow conversion efficiency of Biofrontera AG from 2009 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €18.86 Million | €-2.54 Million | -0.135x | -40.34% |
| 2023-12-31 | €19.98 Million | €-1.92 Million | -0.096x | +49.91% |
| 2022-12-31 | €20.34 Million | €-3.90 Million | -0.192x | -136.13% |
| 2021-12-31 | €57.43 Million | €30.44 Million | 0.530x | +237.21% |
| 2020-12-31 | €7.38 Million | €-2.85 Million | -0.386x | +88.31% |
| 2019-12-31 | €9.96 Million | €-32.89 Million | -3.304x | -302.30% |
| 2018-12-31 | €16.36 Million | €-13.43 Million | -0.821x | +78.83% |
| 2017-12-31 | €3.38 Million | €-13.12 Million | -3.880x | -472.37% |
| 2016-12-31 | €15.84 Million | €-10.74 Million | -0.678x | -133.55% |
| 2015-12-31 | €-4.81 Million | €-9.72 Million | 2.021x | -99.46% |
| 2014-12-31 | €-21.00K | €-7.93 Million | 377.521x | +22297.60% |
| 2013-12-31 | €-4.55 Million | €-7.66 Million | 1.686x | +33.35% |
| 2012-12-31 | €-4.09 Million | €-5.17 Million | 1.264x | +239.05% |
| 2011-12-31 | €-12.53 Million | €-4.67 Million | 0.373x | -14.54% |
| 2010-12-31 | €-12.89 Million | €-5.63 Million | 0.436x | +23.36% |
| 2009-12-31 | €-10.37 Million | €-3.67 Million | 0.354x | -- |